Search results for "INFLAMMASOME"

showing 10 items of 59 documents

Chemotherapy and immunomodulation: from immunogenic chemotherapies to novel therapeutic strategies.

2013

Anticancer immunityCancer ResearchOrganoplatinum Compoundsmedicine.medical_treatmentBreast NeoplasmsT-Lymphocytes RegulatoryImmunomodulationChemoimmunotherapyNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAnthracyclinesCyclophosphamideChemotherapyCell Deathbusiness.industryImmunosuppressionInflammasomeGeneral MedicineOxaliplatinOncologyImmunologyMyeloid-derived Suppressor CellFemaleFluorouracilbusinessImmunosuppressive Agentsmedicine.drugFuture oncology (London, England)
researchProduct

The interplay between the immune system and chemotherapy: emerging methods for optimizing therapy.

2013

Preclinical studies have revealed an unexpected ability of the immune system to contribute to the success of chemotherapy and radiotherapy. Anticancer therapies can trigger immune system activation by promoting the release of danger signals from dying tumor cells and/or the elimination of immunosuppressive cells. We have, however, recently discovered that some chemotherapies, such as 5-fluorouracil and gemcitabine, exert conflicting effects on anticancer immune responses. Although 5-fluorouracil and Gem selectively eliminated myeloid-derived suppressive cells in tumor-bearing rodents, these chemotherapies promoted the release of IL-1β and the development of pro-angiogenic IL-17-producing CD…

Antimetabolites Antineoplasticmedicine.medical_treatmentImmunologyInterleukin-1betaDeoxycytidineImmune systemImmunityNeoplasmsmedicineImmunology and AllergyAnimalsHumansImmunologic FactorsChemotherapyImmunity Cellularbusiness.industryImmunosuppressionInflammasomeChemoradiotherapyGemcitabineGemcitabineRadiation therapyImmunologyMyeloid-derived Suppressor CellCancer researchTh17 CellsFluorouracilbusinessmedicine.drugExpert review of clinical immunology
researchProduct

Does Glycemic Control Modulate the Impairment of NLRP3 Inflammasome Activation in Type 2 Diabetes?

2019

Since mitochondrial dysfunction is associated with NOD-like receptor family protein 3 (NLRP3) activation in type 2 diabetes (T2D), which can eventually lead to an impaired immune response, we set out to determine if glycemic control modulates the effects of T2D on the NLRP3 inflammasome. We have studied leukocytes from 61 diabetic patients [25 with glycated hemoglobin (HbA(1c)) 7% and 36 with HbA(1c) 8%] and 40 healthy controls. Total and mitochondrial reactive oxygen species (ROS) production was enhanced in T2D patients, and mitochondrial ROS was more pronounced in those with poor glycemic control. Levels of gene and protein expression of NLRP3 were decreased in both diabetic groups and mo…

Blood GlucoseMale0301 basic medicineMitochondrial ROSendocrine system diseasesInflammasomesPhysiologyClinical BiochemistryType 2 diabetesmedicine.disease_causeBiochemistrychemistry.chemical_compoundGene expressionoxidative stressGeneral Environmental Scienceintegumentary systemInterleukinInflammasomeMiddle AgedMitochondriaglycaemic controlCytokinesFemaletype 2 diabetesInflammation MediatorsSignal Transductionmedicine.drugmedicine.medical_specialty03 medical and health sciencesmitochondrial functionInternal medicineNLR Family Pyrin Domain-Containing 3 ProteinmedicineHumansBody Weights and MeasuresMolecular BiologyAgedGlycemicGlycated Hemoglobin030102 biochemistry & molecular biologybusiness.industrynutritional and metabolic diseasesCell Biologymedicine.diseaseNLRP3 inflammasome030104 developmental biologyEndocrinologyDiabetes Mellitus Type 2chemistryGeneral Earth and Planetary SciencesGlycated hemoglobinReactive Oxygen SpeciesbusinessBiomarkersOxidative stressAntioxidants & Redox Signaling
researchProduct

The receptor NLRP3 is a transcriptional regulator of TH2 differentiation.

2015

The receptor NLRP3 is involved in the formation of the NLRP3 inflammasome that activates caspase-1 and mediates the release of interleukin 1β (IL-1β) and IL-18. Whether NLRP3 can shape immunological function independently of inflammasomes is unclear. We found that NLRP3 expression in CD4(+) T cells specifically supported a T helper type 2 (TH2) transcriptional program in a cell-intrinsic manner. NLRP3, but not the inflammasome adaptor ASC or caspase-1, positively regulated a TH2 program. In TH2 cells, NLRP3 bound the Il4 promoter and transactivated it in conjunction with the transcription factor IRF4. Nlrp3-deficient TH2 cells supported melanoma tumor growth in an IL-4-dependent manner and …

CD4-Positive T-LymphocytesInflammasomesImmunologyBlotting WesternBiologyInterleukin 21MiceTh2 CellsCell Line TumorNLR Family Pyrin Domain-Containing 3 ProteinImmunology and AllergyCytotoxic T cellAnimalsIL-2 receptorPromoter Regions GeneticInterleukin 3Oligonucleotide Array Sequence AnalysisMice KnockoutCD40integumentary systemReverse Transcriptase Polymerase Chain ReactionZAP70Gene Expression ProfilingCell DifferentiationNeoplasms ExperimentalAsthmaCell biologyGene Expression Regulation NeoplasticMice Inbred C57BLInterleukin 10Interferon Regulatory FactorsInterleukin 12biology.proteinNIH 3T3 CellsTrans-ActivatorsFemaleInterleukin-4Carrier ProteinsProtein BindingSignal TransductionNature immunology
researchProduct

DOP21 Role of P2X7 in intestinal fibrosis and inflammasome activation: Relevance in Crohn′s Disease

2021

Abstract Background Crohn’s disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract whose etiology is unknown. CD is associated with complications such as fibrosis or fistula, which cannot be pharmacologically reversed, requiring repeated surgery. Although a profibrotic effect of the P2X7 receptor has been described in some scenarios such as lung, heart and liver, its role in intestinal fibrosis has not been analysed yet. Given the crosstalk between fibrosis and inflammasome, we aim to analyze the relevance of P2X7 in intestinal fibrosis and inflammasome activation. Methods Surgical intestinal resections of CD patients and healthy ileum of carcinoma patients were obtai…

Crohn's diseasebusiness.industryGastroenterologyCaspase 1InflammasomeGeneral Medicinemedicine.diseaseInflammatory bowel diseaseFibrosisImmunologymedicineInterleukin 18ColitisbusinessIrritable bowel syndromemedicine.drugJournal of Crohn's and Colitis
researchProduct

NLRP3 controls ATM activation in response to DNA damage

2020

The DNA damage response (DDR) is essential to preserve genomic integrity and acts as a barrier to cancer. The ATM pathway orchestrates the cellular response to DNA double strand breaks (DSBs), and its attenuation is frequent during tumorigenesis. Here, we show that NLRP3, a Pattern Recognition Receptor known for its role in the inflammasome complex formation, interacts with the ATM kinase to control the early phase of DDR, independently of its inflammasome activity. NLRP3 down-regulation in human bronchial epithelial cells impairs ATM pathway activation as shown by an altered ATM substrate phosphorylation profile, and due to impaired p53 activation, confers resistance to acute genomic stres…

DNA damage[SDV]Life Sciences [q-bio]medicine.disease_cause03 medical and health sciencesSubstrate-level phosphorylationchemistry.chemical_compound0302 clinical medicineDNA Damage Signalingmedicine[SDV.BBM] Life Sciences [q-bio]/Biochemistry Molecular Biology[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular Biology030304 developmental biologyCancer0303 health sciencesInnate immune systemintegumentary systemChemistryNLRP3 receptorPattern recognition receptorInflammasome3. Good healthCell biology[SDV] Life Sciences [q-bio]030220 oncology & carcinogenesisCarcinogenesisInflammasome complexDNAmedicine.drug
researchProduct

Innate immunity but not NLRP3 inflammasome activation correlates with severity of stable COPD.

2014

Background In models of COPD, environmental stressors induce innate immune responses, inflammasome activation and inflammation. However, the interaction between these responses and their role in driving pulmonary inflammation in stable COPD is unknown. Objectives To investigate the activation of innate immunity and inflammasome pathways in the bronchial mucosa and bronchoalveolar lavage (BAL) of patients with stable COPD of different severity and control healthy smokers and non-smokers. Methods Innate immune mediators (interleukin (IL)-6, IL-7, IL-10, IL-27, IL-37, thymic stromal lymphopoietin (TSLP), interferon γ and their receptors, STAT1 and pSTAT1) and inflammasome components (NLRP3, NA…

EXPRESSIONMaleINTERLEUKIN-6InflammasomesCOPD PathologyChronic Obstructive Pulmonary DiseaseRespiratory SystemImmunity NLRP3 COPDBronchiReceptors Cell SurfaceRespiratory MucosaPULMONARYInterferon-gammaPulmonary Disease Chronic ObstructiveMARKERSThymic Stromal LymphopoietinSPUTUMNLR Family Pyrin Domain-Containing 3 ProteinCytokine Receptor gp130Humans1506HMGB1 ProteinAdaptor Proteins Signal TransducingAgedScience & TechnologyRECEPTORInterleukinsSmoking1103 Clinical SciencesMiddle AgedInterleukin-1 Receptor-Like 1 ProteinImmunity InnateInnate Immunityrespiratory tract diseasesANTIINFLAMMATORY CYTOKINESTAT1 Transcription FactorCase-Control StudiesT-CELLSASTHMACytokinesFemaleCOPD Pathology Innate ImmunityCarrier ProteinsLife Sciences & BiomedicineBronchoalveolar Lavage FluidSMOKERSThorax
researchProduct

ALS monocyte-derived microglia-like cells reveal cytoplasmic TDP-43 accumulation, DNA damage, and cell-specific impairment of phagocytosis associated…

2022

Abstract Background Amyotrophic lateral sclerosis (ALS) is a multifactorial neurodegenerative disease characterised by the loss of upper and lower motor neurons. Increasing evidence indicates that neuroinflammation mediated by microglia contributes to ALS pathogenesis. This microglial activation is evident in post-mortem brain tissues and neuroimaging data from patients with ALS. However, the role of microglia in the pathogenesis and progression of amyotrophic lateral sclerosis remains unclear, partly due to the lack of a model system that is able to faithfully recapitulate the clinical pathology of ALS. To address this shortcoming, we describe an approach that generates monocyte-derived mi…

General NeuroscienceAmyotrophic Lateral SclerosisImmunologyNeurodegenerative DiseasesMonocytesInflammasomeDNA-Binding ProteinsCellular and Molecular NeurosciencePhagocytosisNeurologyDisease ProgressionHumansSettore MED/26 - NeurologiaMicrogliaTDP-43 inclusionsAmyotrophic lateral sclerosiDNA DamageJournal of Neuroinflammation
researchProduct

Variability of Accessory Proteins Rules the SARS-CoV-2 Pathogenicity

2020

AbstractThe coronavirus disease 2019 (COVID-19) is caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) which is pandemic with an estimated fatality rate less than 1% is ongoing. SARS-CoV-2 accessory proteins ORF3a, ORF6, ORF7a, ORF7b, ORF8, and ORF10 with putative functions to manipulate host immune mechanisms such as interferons, immune signaling receptor NLRP3 (NOD-, LRR-, and pyrin domain-containing 3) inflammasome, inflammatory cytokines such as interleukin 1β(IL-1β) are critical in COVID-19 pathology. Outspread variations of each of the six accessory proteins of all complete proteomes (available as of October 26, 2020, in the National Center for Biotechnology Inf…

GeneticsSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ProteomeCase fatality ratemedicineInflammasomeNodBiologyReceptorPyrin domainmedicine.drugProinflammatory cytokine
researchProduct

Immune effects of 5-fluorouracil

2012

Cytotoxic anticancer drugs can promote antitumor immune responses. The anticancer activity of 5-fluorouracil (5FU) relies on the restoration of T-cell immunity following the elimination of myeloid-derived suppressor cells (MDSCs). We have recently discovered that the 5FU-driven activation of the NLRP3 inflammasome in MDSCs promotes tumor angiogenesis by eliciting TH17 responses that compromise anticancer immunity. This underscores the need to combine 5-FU with NLRP3 inhibitors to prevent tumor progression.

IL1business.industryImmunologychemical and pharmacologic phenomenaInflammasomemyeloid derived suppressor cellsfluorouracillaw.inventionImmune systemNLRP3OncologyinflammasomelawTumor progressionImmunityFluorouracilImmunologyMyeloid-derived Suppressor CellmedicineImmunology and AllergyCytotoxic T cellSuppressorbusinessAuthor's Viewmedicine.drugOncoImmunology
researchProduct